Conventional Synthetic Disease-modifying Antirheumatic Drugs (DMARDs) for the Treatment of Non-infectious Uveitis

Tappeiner, Christoph; Rath, Thomas; Heiligenhaus, Arnd (2018). Conventional Synthetic Disease-modifying Antirheumatic Drugs (DMARDs) for the Treatment of Non-infectious Uveitis. Klinische Monatsblätter für Augenheilkunde, 235(5), pp. 562-567. Ferdinand Enke Verlag 10.1055/a-0586-3931

[img] Text
a-0586-3931.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (103kB) | Request a copy

The first-line therapy of uveitis normally consists of topical and/or systemic corticosteroid use. To achieve long-term ocular quiescence, to prevent uveitic secondary complications, to allow corticosteroid sparing and to avoid corticosteroid-related adverse effects, the application of immunosuppressive drugs (disease modifying antirheumatic drugs; DMARDs) is often necessary during the course of the disease. This article presents a structural overview of the most important conventional synthetic DMARDs, their indication, adverse events and interdisciplinary monitoring.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Tappeiner, Christoph

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0023-2165

Publisher:

Ferdinand Enke Verlag

Language:

German

Submitter:

Christoph Tappeiner

Date Deposited:

31 Jan 2019 09:23

Last Modified:

22 Oct 2019 17:58

Publisher DOI:

10.1055/a-0586-3931

PubMed ID:

29739025

BORIS DOI:

10.7892/boris.123077

URI:

https://boris.unibe.ch/id/eprint/123077

Actions (login required)

Edit item Edit item
Provide Feedback